RESUMO
INTRODUCTION: Allergic rhinitis (AR) is increasingly prevalent in India, affecting a significant portion of the population and adversely impacting their quality of life. This nationwide survey aimed to explore the perceptions and clinical preferences of Indian physicians regarding the perceived prevalence, common symptoms, and various available treatments for AR. METHODS: This cross-sectional, observational, digital questionnaire-based survey was conducted from September 2022 to March 2023, involving physicians sharing insights on prevalence rates, diagnostic approaches, medication preferences, and immunotherapy practices in AR management. RESULTS: A total of 1608 physicians participated in this survey. The majority of physicians (n=684, 42.5%) reported that the prevalence of AR in routine clinical practice is between 21 and 40%. Physicians also noted a substantial burden of AR with asthma (n=626, around 40%). Total IgE count was reported as a mandatory test for the diagnosis of AR by 47.5% of physicians (n=764). For the management of mild cases of seasonal or perennial AR, 980 (60.9%) physicians preferred fexofenadine as an oral antihistamine of choice. Fluticasone furoate was the preferred intranasal corticosteroid (INCS) option (67.1% of physicians (n=1079)), for the management of patients with moderate to severe AR, the most recommended duration of INCS therapy was two to four months (40.9% of physicians). Doctors recommended a montelukast and antihistamine combination in mild AR (n=152, 9.5%), mild AR not responding to antihistamine alone (n=291, 18.1%), moderate to severe AR along with INCS (n=252, 15.7%), and AR with mild asthma (n=74, 4.6%). The majority of physicians (n=1512, 75.6%) preferred using fexofenadine in combination with montelukast for the management of AR. The majority of physicians (n=839, 52.2%) opined that the efficacy rate of oral montelukast-fexofenadine was 60-90% in the management of mild-moderate AR. Around 55.3% of physicians (n=889) had not used immunotherapy in their clinical practice. CONCLUSION: These observations offer a holistic view of how Indian physicians perceive the management of AR, a condition highly prevalent in India and often associated with asthma. It also highlights the treatment strategies employed in their day-to-day clinical practice.
RESUMO
Allergic rhinitis (AR) is considered a trivial disease and is often self-treated with over-the-counter drugs and home remedies. However, AR is a contributing risk factor for asthma associated with complications, including chronic cough, eosinophilic esophagitis, and otitis media with effusion. In AR, inflammation is primarily mediated by histamines. Guidelines advise using second-generation oral H1 antihistamines as the primary treatment for AR. Second-generation H1 antihistamines strongly prefer the H1 receptor, limiting their ability to enter the central nervous system. Thus, they have minimal adverse effects. Among these H1 antihistamines, bilastine is highly specific for H1 receptors with a slight affinity for other receptors. It has a rapid and prolonged action, which reduces the need for frequent dosing and has better compliance. In the long term, bilastine is well-tolerated with minimal adverse effects. It is not associated with drug interactions, so dosage adjustment is unnecessary. Bilastine does not penetrate the brain and is nonsedating at 80 mg once daily. The low possibility of drug-drug interactions and pharmacokinetics of bilastine makes it suitable for elderly patients, even with compromised hepatic and renal function, without dose adjustment. This review comprehensively discusses the guidelines and the role of bilastine in treating AR. How to cite this article: Tiwaskar M, Vora A, Tewary K, et al. Role of Bilastine in Allergic Rhinitis: A Narrative Review. J Assoc Physicians India 2023;71(11):58-61.
Assuntos
Piperidinas , Rinite Alérgica , Humanos , Rinite Alérgica/tratamento farmacológico , Piperidinas/uso terapêutico , Piperidinas/farmacocinética , Benzimidazóis/uso terapêutico , Benzimidazóis/farmacocinética , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Antagonistas dos Receptores Histamínicos H1/administração & dosagemRESUMO
The prevalence of Allergic rhinitis (AR) is associated with a variety of environmental allergens and the level of exposure is through inhalation, or ingestion. It is clear from several studies and guidelines that screening and identification of various allergens in a particular region can facilitate in diagnosing, treating and formulating preventive strategies against AR. To study the allergen patterns in patients with Moderate to severe persistent allergic rhinitis from Central India. Male/female of 6 to 63 years age group, presenting with itching of the nose, sneezing, rhinorrhoea, nasal congestion and nasal obstruction. Patients suffering from infective pathology of nose and sinuses. The study group comprised of 1350 male/female of the age group between 6 and 63 years. Modified skin prick test was performed according to the method of Pepys and Bernstein. The ratio of allergen wheal and histamine wheal was used to evaluate the results. The reactions with wheal diameter 3 mm or greater than the reading in the negative control were considered as positive reaction. Results of the study indicate that in Central India, the common allergens are pollens (78.5%), insects (64.5%), dust (38.5%), dust mites (18%) and food (10%) causing moderate to severe persistent allergic rhinitis. The study provided an insight and identified the allergen pattern in Central India. The results were of great help in counseling for avoidance therapy and for deciding allergen specific immunotherapy which is the standard treatment protocol to modify natural course of allergic rhinitis at this point of time.